|
|
| | Thailanstatin D Basic information |
| Product Name: | Thailanstatin D | | Synonyms: | Thailanstatin D;1,6-Dioxaspiro[2.5]octane-5-acetic acid, 7-[(1E,3E)-5-[(2S,3S,5R,6R)-5-[[(2Z,4S)-4-(acetyloxy)-1-oxo-2-penten-1-yl]amino]tetrahydro-3,6-dimethyl-2H-pyran-2-yl]-3-methyl-1,3-pentadien-1-yl]-, (3S,5S,7S)-;2-[(3S,5S,7S)-7-[(1E,3E)-5-[(2S,3S,5R,6R)-5-[(2Z,4S)-4-(acetyloxy)pent-2-enamido]-3,6-dimethyloxan-2-yl]-3-methylpenta-1,3-dien-1-yl]-1,6-dioxaspiro[2.5]octan-5-yl]acetic acid | | CAS: | 1609105-89-6 | | MF: | C28H41NO8 | | MW: | 519.63 | | EINECS: | | | Product Categories: | ADC | | Mol File: | 1609105-89-6.mol |  |
| | Thailanstatin D Chemical Properties |
| Boiling point | 722.3±60.0 °C(Predicted) | | density | 1.19±0.1 g/cm3(Predicted) | | pka | 4.37±0.10(Predicted) |
| | Thailanstatin D Usage And Synthesis |
| Uses | Thailanstatin D, an analogue of Thailanstatin A, is able to inhibit AR-V7 gene splicing by interfering the interaction between U2AF65 and SAP155 and preventing them from binding to polypyrimidine tract located between the branch point and the 3' splice site. Thailanstatin D exhibits a potent tumor inhibitory effect on human CRPC xenografts leading to cell apoptosis[1]. | | in vivo | Thailanstatin D (300 μg/kg; ALZET osmotic pumps; daily for 4 days) significantly inhibits the tumor growth[1]. | Animal Model: | NOD-SCID mice ( Mice bearing 22RV1 xenografts)[1] | | Dosage: | 300 μg/kg | | Administration: | ALZET osmotic pumps; daily for 4 days | | Result: | Significantly inhibited the tumor growth.
|
| | References | [1] Wang B, et al. Developing new targeting strategy for androgen receptor variants in castration resistant prostate cancer. Int J Cancer. 2017;141(10):2121-2130. DOI:10.1002/ijc.30893 |
| | Thailanstatin D Preparation Products And Raw materials |
|